Sign in

CIK 0001880438

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
820606654
Phone
+1 650-331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion +392,433 2,044,069
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion +74,230 386,645
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Purchase +166,666 $15.00 $2.5M 2,210,735
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion · Series A Convertible Preferred Stock −1,651,636 0
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion · Series A Convertible Preferred Stock −312,415 0
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion · Series B Convertible Preferred Stock −392,433 0
2022-03-29 Adjuvant Global Health Technology Fund, L.P. 10% owner Conversion · Series B Convertible Preferred Stock −74,230 0
2022-03-29 RA CAPITAL MANAGEMENT, L.P. 10% owner Conversion +1,699,998 1,699,998
2022-03-29 RA CAPITAL MANAGEMENT, L.P. 10% owner Purchase +1,551,053 $15.00 $23.3M 3,251,051
2022-03-29 RA CAPITAL MANAGEMENT, L.P. 10% owner Conversion +299,999 299,999
2022-03-29 RA CAPITAL MANAGEMENT, L.P. 10% owner Purchase +115,613 $15.00 $1.7M 415,612
2022-03-29 RA CAPITAL MANAGEMENT, L.P. 10% owner Conversion · Series B Preferred Stock −1,699,998 0
2022-03-29 RA CAPITAL MANAGEMENT, L.P. 10% owner Conversion · Series B Preferred Stock −299,999 0
2022-03-29 Zakrzewski Joseph S Director Conversion +98,199 98,199
2022-03-29 Zakrzewski Joseph S Director Conversion · Series A Convertible Preferred Stock −98,199 0
2022-03-29 Readnour Robin Shane Director Conversion +285,156 285,156
2022-03-29 Readnour Robin Shane Director Conversion +333,135 333,135
2022-03-29 Readnour Robin Shane Director Conversion +61,491 346,647
2022-03-29 Readnour Robin Shane Director Conversion +71,839 404,974
2022-03-29 Readnour Robin Shane Director Purchase +70,716 $15.00 $1.1M 417,363

Page 18 of 20 · 385 trades